PepGen Inc. (PEPG) Income Statement

Revenue is effectively unavailable in the supplied data, which means reported revenue growth rates cannot be meaningfully interpreted. The absence of top-line revenue suggests the company remains in a pre-commercial, development-stage profile, and investors should monitor whether any future collaboration or licensing income emerges. Without revenue, the income statement analysis rests entirely on the expense base and its trajectory.

The operating loss improvement tracks closely with R&D reduction, with SG&A remaining comparatively flat at roughly $5-6M per quarter. This pattern suggests that operating leverage in the traditional sense is not present, since losses scale with development spending rather than with revenue growth. Investors should view the narrowing loss as the result of program prioritization rather than improving unit economics.

The cost structure is heavily weighted toward research and development, which is typical of clinical-stage biotechnology firms but leaves the company highly sensitive to trial timing and spending decisions. SG&A discipline appears consistent, though its absolute level is small relative to R&D. The data does not disclose program-level detail, so the composition of R&D spend cannot be assessed from these figures alone.